Navigation Links
Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
Date:9/15/2010

xpert in the use of pharmacogenetics in clinical drug discovery and development, today announce a strategic partnership to develop software decision tools that will provide biopharmaceutical companies with rapid and extensive access to the world's leading academic biomarker research groups. The new tools will enable commercial biomarker research teams to comprehensively explore global biomarker resources to identify genes and gene sequences, as well as the researchers and clinicians relevant to their targeted therapy research.

The new software, which is expected to be launched in 2011, is based on the Diaceutics Fusion platform, the leading personalised medicine planning software application for targeted therapy development teams, and the London Genetics Biomarker Pathway platform. The tools to be developed under the strategic partnership will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development. The expressions of interest, requesting access to patient samples and investigator networks, will be sent to academic biomarker research teams globally, including London Genetics' own network of over 3,000 investigators in a broad range of therapeutic areas and technology disciplines. In this way, partners can be rapidly identified and collaborative projects instigated.

"We are delighted to partner with London Genetics, leverage their biomarker expertise, and together build tools that will address a key problem for therapy development teams," said Peter Keeling, CEO of Diaceutics. "Biomarker research is often limited because teams don't know the capabilities of external research centers and miss potential collaborations which could accelerate their targeted therapy development."

"This strategic alliance with Diaceutics fits closely with our overall goal to expedite pharmacogenetic and biomarker partnerships between industry and academia for more effective targeted drug deve
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
2. London Genetics Conference Proceedings Published in Drug Discovery Today
3. First Awards Made by London Genetics Proof-of-Concept Fund
4. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
5. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
6. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
7. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
8. Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
9. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
10. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
11. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... YORK, Sept. 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0611073/Global-Intravascular-Ultrasound-IVUS-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_I This ... Ultrasound (IVUS) in US$ Million by the ...
... Pa., Sept. 8, 2011 Auxilium Pharmaceuticals, Inc. ... company, today announced additional three year recurrence data ... Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX ... of adult Dupuytren,s contracture patients with a palpable ...
Cached Medicine Technology:Global Intravascular Ultrasound (IVUS) Industry 2Global Intravascular Ultrasound (IVUS) Industry 3Global Intravascular Ultrasound (IVUS) Industry 4Global Intravascular Ultrasound (IVUS) Industry 5Global Intravascular Ultrasound (IVUS) Industry 6Global Intravascular Ultrasound (IVUS) Industry 7Global Intravascular Ultrasound (IVUS) Industry 8Global Intravascular Ultrasound (IVUS) Industry 9Global Intravascular Ultrasound (IVUS) Industry 10Global Intravascular Ultrasound (IVUS) Industry 11Global Intravascular Ultrasound (IVUS) Industry 12Global Intravascular Ultrasound (IVUS) Industry 13Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 2Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 3Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 4Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 5Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 6Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 7Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 8Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 9
(Date:7/13/2014)... Advanced boilers are preferred over ... of fossil fuels, produce high-capacity power, emit fewer ... global warming and climate change concerns, many countries ... gas emissions and pollutants coming from fossilfuel-based power ... global advance boilers market., The global power rental ...
(Date:7/13/2014)... 13, 2014 According to a ... Computing Market by Component (processor, GPU, DSP, connectivity), ... Medical), and Geography - Forecast and Analysis to ... Processing & Computing Market is expected to reach ... of 20.75% from 2014 to 2020. , Browse ...
(Date:7/13/2014)... A Massachusetts couple who have done ... associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) finally ... regulators, as they presented poignant testimony on the second ... (FDA) advisory panel meeting convened to address the issue, ... Democrat and Chronicle, Dr. Hooman Noorchashm and his wife, ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... WASHINGTON, Sept. 25 The following was,released today by ... tonight, the House of Representatives is expected to vote ... for,illegal immigrants and uses budgetary gimmicks to capture new ... private insurance and,onto government-run health care. Here,s just a ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... services, today announced that it has,filed a universal ... (SEC) for the periodic offering and sale of ... common stock and warrants,after the SEC declares the ...
... CHARLOTTESVILLE, VA (September 25, 2007) Birds, fish and ... generally cannot: re-grow damaged or lost inner ear hair ... deficiencies and disabling balance problems in an estimated 250 ... treatments, research and development efforts have been hindered by ...
... Under Medicare Creates Two-Tiered System of Cancer Care ... Face Avoidable Blood Transfusions, HOUSTON, Sept. 25 ... over 1,100 oncologists across the,country, today expressed "deep ... for Medicare and Medicaid Services (CMS) -- the ...
... American Society of,Transplantation (AST) Past President Jeffrey ... Representatives, Information, Policy, Census and,National Archives Subcommittee of ... subcommittee to use public policy and,technology to strengthen ... Dr. Crippin, over 97,000 individuals are awaiting a,life-saving ...
... Sept. 25 The HealthCentral Network,Inc. ... an author,and psychotherapist who has asthma and ... expert. Miller, dubbed,"Allergic Girl", first gained online ... Nuts", which catalogues her daily challenges with ...
Cached Medicine News:Health News:'Compromise' SCHIP Deal Substitutes Ideology for Common Sense 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 3Health News:Study expected to boost research for hearing and balance therapies 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 3Health News:American Society of Transplantation's Past President Testifies Before Congress at Forum on Organ Donation 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 3
CRP Liquid Conrtols level 3...
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Medicine Products: